Organon & Co. Repayments of Long-Term Debt
Organon & Co. (OGN) reported Repayments of Long-Term Debt of $32.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-07-31
- Organon & Co. repayments of long-term debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. repayments of long-term debt for the quarter ending 2026-03-31 was $32.00M, a 65.59% decline year-over-year.
- Organon & Co. repayments of long-term debt for the quarter ending 2025-12-31 was $507.00M, a 233.55% increase year-over-year.
- Organon & Co. repayments of long-term debt for the quarter ending 2025-09-30 was $372.00M, a 18500.00% increase year-over-year.
- Organon & Co. repayments of long-term debt for fiscal 2025 was $1.51B, a 26.40% increase from fiscal 2024.
- Organon & Co. repayments of long-term debt for fiscal 2024 was $1.20B, a 254.14% increase from fiscal 2023.
- Organon & Co. repayments of long-term debt for fiscal 2023 was $338.00M, a 212.96% increase from fiscal 2022.
- Organon & Co. repayments of long-term debt for fiscal 2022 was $108.00M, a 3.57% decline from fiscal 2021.
| Period end | Repayments of Long-term Debt | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 6 month as first filed | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $32.00M 10-Q · filed 2026-07-31 | $539.00M derived: sum of 3 quarters · filed 2026-07-31 | $911.00M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $32.00M 10-Q · filed 2026-05-04 | $539.00M derived: sum of 2 quarters · filed 2026-05-04 | $911.00M derived: sum of 3 quarters · filed 2026-05-04 | $1.45B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-12-31 | $507.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $879.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.42B derived: sum of 3 quarters · filed 2026-07-31 | $1.51B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $372.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $913.00M derived: sum of 2 quarters · filed 2026-07-31 | $1.01B 10-Q · filed 2025-11-10 | $1.16B derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-06-30 | $541.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $634.00M 10-Q · filed 2026-07-31 | $786.00M derived: sum of 3 quarters · filed 2026-07-31 | $788.00M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $93.00M 10-Q · filed 2026-05-04 | $245.00M derived: sum of 2 quarters · filed 2026-05-04 | $247.00M derived: sum of 3 quarters · filed 2026-05-04 | $1.29B derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $152.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $154.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.20B derived: sum of 3 quarters · filed 2026-02-24 | $1.20B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.04B derived: sum of 2 quarters · filed 2025-11-10 | $1.04B 10-Q · filed 2025-11-10 | $1.05B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $1.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.04B 10-Q · filed 2025-08-06 | $1.04B derived: sum of 3 quarters · filed 2026-02-24 | $1.05B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-02 | $4.00M derived: sum of 2 quarters · filed 2026-02-24 | $6.00M derived: sum of 3 quarters · filed 2026-02-24 | $88.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.00M derived: sum of 2 quarters · filed 2026-02-24 | $86.00M derived: sum of 3 quarters · filed 2026-02-24 | $338.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $84.00M derived: sum of 2 quarters · filed 2024-11-01 | $336.00M 10-Q · filed 2024-11-01 | $338.00M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2023-06-30 | $82.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $334.00M 10-Q · filed 2024-08-07 | $336.00M derived: sum of 3 quarters · filed 2025-11-10 | $336.00M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2023-03-31 | $252.00M 10-Q · filed 2024-05-03 | $254.00M derived: sum of 2 quarters · filed 2025-11-10 | $254.00M derived: sum of 3 quarters · filed 2025-11-10 | $358.00M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2022-12-31 | $2.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $2.00M derived: sum of 2 quarters · filed 2025-11-10 | $106.00M derived: sum of 3 quarters · filed 2025-11-10 | $108.00M 10-K/A · filed 2025-11-10 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $104.00M derived: sum of 2 quarters · filed 2023-11-03 | $106.00M 10-Q · filed 2023-11-03 | $208.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | $104.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $106.00M 10-Q · filed 2023-08-09 | $208.00M derived: sum of 3 quarters · filed 2024-02-26 | $218.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-05 | $104.00M derived: sum of 2 quarters · filed 2024-02-26 | $114.00M derived: sum of 3 quarters · filed 2024-02-26 | $114.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $112.00M derived: sum of 2 quarters · filed 2024-02-26 | $112.00M derived: sum of 3 quarters · filed 2024-02-26 | $112.00M 10-K · filed 2024-02-26 | ||
| 2021-12-23 | $100.00M 10-K · filed 2022-03-21 | |||||
| 2021-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $10.00M derived: sum of 2 quarters · filed 2022-11-04 | $10.00M 10-Q · filed 2022-11-04 | $10.00M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2022-08-05 | $118.00M 10-Q · filed 2021-08-16 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |